SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
SEC Accession No. 0001104659-21-023339
Filing Date
2021-02-16
Accepted
2021-02-16 11:08:07
Documents
1
Group Members
FORESITE CAPITAL FUND V, L.P.FORESITE CAPITAL MANAGEMENT IV, LLCFORESITE CAPITAL MANAGEMENT V, LLCFORESITE CAPITAL OPPORTUNITY FUND V, L.P.FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLCJAMES TANANBAUM

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13G/A tm216635d5_sc13ga.htm SC 13G/A 132476
  Complete submission text file 0001104659-21-023339.txt   134368
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Subject) CIK: 0001549595 (see all company filings)

IRS No.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: SC 13G/A | Act: 34 | File No.: 005-91591 | Film No.: 21634278
SIC: 2834 Pharmaceutical Preparations

Mailing Address 600 MONTGOMERY STREET, SUITE 4500 SAN FRANCISCO CA 94111
Business Address 600 MONTGOMERY STREET, SUITE 4500 SAN FRANCISCO CA 94111 415-877-4887
Foresite Capital Fund IV, L.P. (Filed by) CIK: 0001704131 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A